Prestige Consumer Healthcare (NYSE:PBH) Stock Price Down 15.9% – Should You Sell?

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s stock price dropped 15.9% during trading on Thursday. The stock traded as low as $45.48 and last traded at $44.7850. 100,272 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 559,134 shares. The stock had previously closed at $53.28.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PBH. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, September 22nd. Zacks Research cut Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 29th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $67.67.

Prestige Consumer Healthcare Stock Down 16.4%

The firm has a market cap of $2.11 billion, a PE ratio of 12.43, a P/E/G ratio of 1.55 and a beta of 0.30. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The firm’s 50-day moving average price is $48.49 and its two-hundred day moving average price is $53.99.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 5th. The company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.07 by $0.06. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm had revenue of $336.31 million for the quarter, compared to analyst estimates of $329.14 million. During the same period last year, the business earned $1.07 EPS. Prestige Consumer Healthcare’s revenue for the quarter was up 22.7% compared to the same quarter last year. As a group, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in PBH. BlackRock Inc. acquired a new position in Prestige Consumer Healthcare during the second quarter worth approximately $370,187,000. Dimensional Fund Advisors LP boosted its holdings in shares of Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after acquiring an additional 91,710 shares during the period. Rice Hall James & Associates LLC acquired a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $32,602,000. The Manufacturers Life Insurance Company acquired a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $31,135,000. Finally, Bank of America Corp DE purchased a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at $26,277,000. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.